Terumo (OTCMKTS:TRUMY) Raised to “Strong-Buy” at Zacks Research

Terumo (OTCMKTS:TRUMY – Get Free Report) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Tuesday, Zacks reports.

Separately, Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, the company has a consensus rating of “Strong Buy”.

Get Terumo alerts:

Get Our Latest Report on Terumo

Terumo Stock Down 3.0%

Shares of OTCMKTS:TRUMY opened at $14.15 on Tuesday. Terumo has a 52-week low of $12.08 and a 52-week high of $17.81. The firm has a fifty day moving average of $15.11 and a 200 day moving average of $14.22. The firm has a market capitalization of $20.87 billion, a PE ratio of 19.93 and a beta of 0.77. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.37 and a current ratio of 2.19.

Terumo (OTCMKTS:TRUMY – Get Free Report) last released its earnings results on Friday, August 7th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. Terumo had a return on equity of 10.44% and a net margin of 13.83%. The business had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.84 billion. As a group, research analysts anticipate that Terumo will post 0.86 EPS for the current fiscal year.

About Terumo

(Get Free Report)

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells products used in hospitals, clinics and other healthcare settings. Founded in 1921 by a group of Japanese medical doctors, the company initially produced clinical thermometers and has since expanded into a global provider of medical devices and related services.

Terumo’s principal businesses include cardiac and vascular products, blood and cell technologies, and general hospital solutions.

Recommended Stories

• Five stocks we like better than Terumo
• UnitedHealth Beats on Earnings, But Investors Question Growth Path
• Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?

Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.